Literature DB >> 12628374

The dual activity of pyruvate kinase type M2 from chromatin extracts of neoplastic cells.

Jan Ignacak1, Maria Barbara Stachurska.   

Abstract

Pyruvate kinase type M(2) from Morris hepatoma 7777 tumour cell nuclei and cytosol, in contrast to types L and M(2) from nuclei and cytosol of normal rat liver, shows the histone H(1) kinase activity. Moreover, in the presence of L-cysteine and without ADP it converts 2-phosphoenolpyruvate (PEP) to pyruvate while in the presence of L-arginine or L-histidine does not. L-Cysteine markedly stimulates the activity of histone H(1) kinase transferring a phosphate group from PEP to, as results suggested, the epsilon -amino group of L-lysine of histone H(1). This, L-cysteine which is known to inhibit the activity of pyruvate kinase type M(2) from neoplastic cells transfering a phosphate from PEP to ADP, can act as a control factor champing the direction of enzymatic reaction in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12628374     DOI: 10.1016/s1096-4959(02)00283-x

Source DB:  PubMed          Journal:  Comp Biochem Physiol B Biochem Mol Biol        ISSN: 1096-4959            Impact factor:   2.231


  13 in total

1.  PKM2: a gatekeeper between growth and survival.

Authors:  Isaac Harris; Susan McCracken; Tak Wah Mak
Journal:  Cell Res       Date:  2011-12-20       Impact factor: 25.617

2.  Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase.

Authors:  Xueliang Gao; Haizhen Wang; Jenny J Yang; Xiaowei Liu; Zhi-Ren Liu
Journal:  Mol Cell       Date:  2012-02-02       Impact factor: 17.970

Review 3.  Pyruvate kinase M2: A simple molecule with complex functions.

Authors:  Mohammed Alquraishi; Dexter L Puckett; Dina S Alani; Amal S Humidat; Victoria D Frankel; Dallas R Donohoe; Jay Whelan; Ahmed Bettaieb
Journal:  Free Radic Biol Med       Date:  2019-08-08       Impact factor: 7.376

Review 4.  Metabolic checkpoints in activated T cells.

Authors:  Ruoning Wang; Douglas R Green
Journal:  Nat Immunol       Date:  2012-09-18       Impact factor: 25.606

Review 5.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.

Authors:  Patrick S Ward; Craig B Thompson
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

6.  The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.

Authors:  K Koss; R F Harrison; J Gregory; S J Darnton; M R Anderson; J A Z Jankowski
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

7.  Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation.

Authors:  Katherine Tech; Andrey P Tikunov; Hamza Farooq; A Sorana Morrissy; Jessica Meidinger; Taylor Fish; Sarah C Green; Hedi Liu; Yisu Li; Andrew J Mungall; Richard A Moore; Yussanne Ma; Steven J M Jones; Marco A Marra; Matthew G Vander Heiden; Michael D Taylor; Jeffrey M Macdonald; Timothy R Gershon
Journal:  Cancer Res       Date:  2017-05-17       Impact factor: 12.701

Review 8.  A critical review of the role of M2PYK in the Warburg effect.

Authors:  Robert A Harris; Aron W Fenton
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-29       Impact factor: 10.680

9.  Isoform switch of pyruvate kinase M1 indeed occurs but not to pyruvate kinase M2 in human tumorigenesis.

Authors:  Cheng Zhan; Li Yan; Lin Wang; Jun Ma; Wei Jiang; Yongxing Zhang; Yu Shi; Qun Wang
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

Review 10.  Dysregulated metabolism contributes to oncogenesis.

Authors:  Matthew D Hirschey; Ralph J DeBerardinis; Anna Mae E Diehl; Janice E Drew; Christian Frezza; Michelle F Green; Lee W Jones; Young H Ko; Anne Le; Michael A Lea; Jason W Locasale; Valter D Longo; Costas A Lyssiotis; Eoin McDonnell; Mahya Mehrmohamadi; Gregory Michelotti; Vinayak Muralidhar; Michael P Murphy; Peter L Pedersen; Brad Poore; Lizzia Raffaghello; Jeffrey C Rathmell; Sharanya Sivanand; Matthew G Vander Heiden; Kathryn E Wellen
Journal:  Semin Cancer Biol       Date:  2015-10-08       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.